XML 96 R85.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Segment Reporting - Sales of Company's Products (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended
--- | --- | ---
Sep. 30, 2018 | Sep. 30, 2017 | Sep. 30, 2018 | Sep. 30, 2017
Segment Reporting Information [Line Items] |  |  |  |
Sales | $ 10,794 | $ 10,325 | $ 31,296 | $ 29,689
Proceeds from sale of marketing rights |  |  | 81 | 60
Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 10,734 | 10,256 | 31,230 | 29,289
Other |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 60 | 69 | 66 | 400
United States |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 5,030 | 4,594 | 13,425 | 13,096
United States | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 5,010 | 4,587 | 13,324 | 13,023
United States | Other |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 20 | 7 | 101 | 73
International |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 5,764 | 5,732 | 17,871 | 16,593
International | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 5,725 | 5,669 | 17,906 | 16,266
International | Other |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 39 | 63 | (35) | 327
Total Pharmaceutical segment sales | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 9,658 | 9,156 | 27,859 | 26,101
Total Pharmaceutical segment sales | Operating Segments | Keytruda |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 1,889 | 1,047 | 5,020 | 2,512
Total Pharmaceutical segment sales | Operating Segments | Emend |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 123 | 137 | 396 | 413
Total Pharmaceutical segment sales | Operating Segments | Temodar |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 46 | 68 | 159 | 198
Total Pharmaceutical segment sales | Operating Segments | Alliance revenue - Lynparza |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 49 | 5 | 125 | 5
Total Pharmaceutical segment sales | Operating Segments | Alliance revenue - Lenvima |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 43 | 0 | 78 | 0
Total Pharmaceutical segment sales | Operating Segments | Gardasil/Gardasil 9 |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 1,048 | 675 | 2,317 | 1,675
Total Pharmaceutical segment sales | Operating Segments | ProQuad/M-M-R II/Varivax |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 525 | 519 | 1,343 | 1,273
Total Pharmaceutical segment sales | Operating Segments | Pneumovax 23 |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 214 | 229 | 586 | 558
Total Pharmaceutical segment sales | Operating Segments | RotaTeq |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 191 | 179 | 540 | 525
Total Pharmaceutical segment sales | Operating Segments | Zostavax |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 54 | 234 | 163 | 547
Total Pharmaceutical segment sales | Operating Segments | Bridion |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 217 | 185 | 661 | 495
Total Pharmaceutical segment sales | Operating Segments | Noxafil |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 188 | 162 | 551 | 458
Total Pharmaceutical segment sales | Operating Segments | Invanz |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 137 | 159 | 437 | 445
Total Pharmaceutical segment sales | Operating Segments | Cubicin |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 95 | 91 | 287 | 290
Total Pharmaceutical segment sales | Operating Segments | Cancidas |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 79 | 94 | 257 | 327
Total Pharmaceutical segment sales | Operating Segments | Primaxin |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 72 | 73 | 212 | 206
Total Pharmaceutical segment sales | Operating Segments | Simponi |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 210 | 219 | 673 | 602
Total Pharmaceutical segment sales | Operating Segments | Remicade |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 135 | 214 | 459 | 651
Total Pharmaceutical segment sales | Operating Segments | Belsomra |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 66 | 56 | 191 | 150
Total Pharmaceutical segment sales | Operating Segments | Isentress/Isentress HD |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 275 | 310 | 860 | 896
Total Pharmaceutical segment sales | Operating Segments | Zepatier |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 104 | 468 | 347 | 1,363
Total Pharmaceutical segment sales | Operating Segments | Zetia |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 165 | 320 | 696 | 1,021
Total Pharmaceutical segment sales | Operating Segments | Vytorin |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 92 | 142 | 414 | 565
Total Pharmaceutical segment sales | Operating Segments | Atozet |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 84 | 59 | 258 | 171
Total Pharmaceutical segment sales | Operating Segments | Adempas |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 94 | 70 | 238 | 221
Total Pharmaceutical segment sales | Operating Segments | Januvia |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 927 | 1,012 | 2,756 | 2,799
Total Pharmaceutical segment sales | Operating Segments | Janumet |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 563 | 513 | 1,693 | 1,572
Total Pharmaceutical segment sales | Operating Segments | NuvaRing |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 234 | 214 | 686 | 573
Total Pharmaceutical segment sales | Operating Segments | Implanon/Nexplanon |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 186 | 155 | 535 | 503
Total Pharmaceutical segment sales | Operating Segments | Singulair |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 161 | 161 | 521 | 550
Total Pharmaceutical segment sales | Operating Segments | Cozaar/Hyzaar |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 103 | 128 | 348 | 360
Total Pharmaceutical segment sales | Operating Segments | Nasonex |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 71 | 42 | 274 | 266
Total Pharmaceutical segment sales | Operating Segments | Arcoxia |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 83 | 80 | 249 | 272
Total Pharmaceutical segment sales | Operating Segments | Follistim AQ |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 60 | 72 | 198 | 232
Total Pharmaceutical segment sales | Operating Segments | Fosamax |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 45 | 53 | 159 | 180
Total Pharmaceutical segment sales | Operating Segments | Dulera |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 50 | 59 | 149 | 210
Total Pharmaceutical segment sales | Operating Segments | Other Pharmaceutical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 980 | 952 | 3,023 | 3,017
Total Pharmaceutical segment sales | United States | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 4,649 | 4,197 | 12,206 | 11,887
Total Pharmaceutical segment sales | United States | Operating Segments | Keytruda |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 1,109 | 604 | 2,906 | 1,522
Total Pharmaceutical segment sales | United States | Operating Segments | Emend |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 71 | 88 | 239 | 257
Total Pharmaceutical segment sales | United States | Operating Segments | Temodar |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 0 | 0 | 3 | 4
Total Pharmaceutical segment sales | United States | Operating Segments | Alliance revenue - Lynparza |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 33 | 0 | 88 | 0
Total Pharmaceutical segment sales | United States | Operating Segments | Alliance revenue - Lenvima |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 30 | 0 | 49 | 0
Total Pharmaceutical segment sales | United States | Operating Segments | Gardasil/Gardasil 9 |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 740 | 484 | 1,422 | 1,195
Total Pharmaceutical segment sales | United States | Operating Segments | ProQuad/M-M-R II/Varivax |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 429 | 419 | 1,097 | 1,058
Total Pharmaceutical segment sales | United States | Operating Segments | Pneumovax 23 |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 160 | 174 | 394 | 392
Total Pharmaceutical segment sales | United States | Operating Segments | RotaTeq |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 134 | 127 | 384 | 377
Total Pharmaceutical segment sales | United States | Operating Segments | Zostavax |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | (1) | 139 | 16 | 356
Total Pharmaceutical segment sales | United States | Operating Segments | Bridion |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 96 | 63 | 272 | 162
Total Pharmaceutical segment sales | United States | Operating Segments | Noxafil |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 89 | 78 | 257 | 220
Total Pharmaceutical segment sales | United States | Operating Segments | Invanz |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 74 | 93 | 252 | 268
Total Pharmaceutical segment sales | United States | Operating Segments | Cubicin |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 55 | 41 | 150 | 148
Total Pharmaceutical segment sales | United States | Operating Segments | Cancidas |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 2 | 6 | 10 | 17
Total Pharmaceutical segment sales | United States | Operating Segments | Primaxin |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 1 | 5 | 6 | 7
Total Pharmaceutical segment sales | United States | Operating Segments | Simponi |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 0 | 0 | 0 | 0
Total Pharmaceutical segment sales | United States | Operating Segments | Remicade |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 0 | 0 | 0 | 0
Total Pharmaceutical segment sales | United States | Operating Segments | Belsomra |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 23 | 27 | 76 | 72
Total Pharmaceutical segment sales | United States | Operating Segments | Isentress/Isentress HD |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 123 | 143 | 383 | 422
Total Pharmaceutical segment sales | United States | Operating Segments | Zepatier |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 18 | 228 | 8 | 683
Total Pharmaceutical segment sales | United States | Operating Segments | Zetia |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 9 | 65 | 34 | 298
Total Pharmaceutical segment sales | United States | Operating Segments | Vytorin |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 0 | (6) | 11 | 114
Total Pharmaceutical segment sales | United States | Operating Segments | Atozet |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 0 | 0 | 0 | 0
Total Pharmaceutical segment sales | United States | Operating Segments | Adempas |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 0 | 0 | 0 | 0
Total Pharmaceutical segment sales | United States | Operating Segments | Januvia |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 498 | 598 | 1,466 | 1,646
Total Pharmaceutical segment sales | United States | Operating Segments | Janumet |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 225 | 197 | 625 | 640
Total Pharmaceutical segment sales | United States | Operating Segments | NuvaRing |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 193 | 160 | 550 | 425
Total Pharmaceutical segment sales | United States | Operating Segments | Implanon/Nexplanon |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 133 | 110 | 375 | 367
Total Pharmaceutical segment sales | United States | Operating Segments | Singulair |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 5 | 16 | 16 | 28
Total Pharmaceutical segment sales | United States | Operating Segments | Cozaar/Hyzaar |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 4 | 9 | 18 | 15
Total Pharmaceutical segment sales | United States | Operating Segments | Nasonex |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 7 | (23) | 8 | 16
Total Pharmaceutical segment sales | United States | Operating Segments | Arcoxia |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 0 | 0 | 0 | 0
Total Pharmaceutical segment sales | United States | Operating Segments | Follistim AQ |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 26 | 30 | 83 | 104
Total Pharmaceutical segment sales | United States | Operating Segments | Fosamax |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 2 | 4 | 3 | 7
Total Pharmaceutical segment sales | United States | Operating Segments | Dulera |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 44 | 52 | 128 | 191
Total Pharmaceutical segment sales | United States | Operating Segments | Other Pharmaceutical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 317 | 266 | 877 | 876
Total Pharmaceutical segment sales | International | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 5,010 | 4,959 | 15,653 | 14,214
Total Pharmaceutical segment sales | International | Operating Segments | Keytruda |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 780 | 442 | 2,114 | 990
Total Pharmaceutical segment sales | International | Operating Segments | Emend |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 52 | 49 | 157 | 156
Total Pharmaceutical segment sales | International | Operating Segments | Temodar |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 46 | 68 | 156 | 194
Total Pharmaceutical segment sales | International | Operating Segments | Alliance revenue - Lynparza |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 15 | 5 | 37 | 5
Total Pharmaceutical segment sales | International | Operating Segments | Alliance revenue - Lenvima |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 13 | 0 | 29 | 0
Total Pharmaceutical segment sales | International | Operating Segments | Gardasil/Gardasil 9 |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 308 | 191 | 894 | 481
Total Pharmaceutical segment sales | International | Operating Segments | ProQuad/M-M-R II/Varivax |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 96 | 100 | 246 | 215
Total Pharmaceutical segment sales | International | Operating Segments | Pneumovax 23 |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 54 | 56 | 192 | 166
Total Pharmaceutical segment sales | International | Operating Segments | RotaTeq |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 57 | 52 | 156 | 148
Total Pharmaceutical segment sales | International | Operating Segments | Zostavax |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 56 | 94 | 147 | 191
Total Pharmaceutical segment sales | International | Operating Segments | Bridion |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 120 | 122 | 389 | 333
Total Pharmaceutical segment sales | International | Operating Segments | Noxafil |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 99 | 83 | 294 | 237
Total Pharmaceutical segment sales | International | Operating Segments | Invanz |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 62 | 66 | 185 | 177
Total Pharmaceutical segment sales | International | Operating Segments | Cubicin |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 40 | 50 | 137 | 141
Total Pharmaceutical segment sales | International | Operating Segments | Cancidas |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 77 | 88 | 247 | 310
Total Pharmaceutical segment sales | International | Operating Segments | Primaxin |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 71 | 68 | 206 | 199
Total Pharmaceutical segment sales | International | Operating Segments | Simponi |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 210 | 219 | 673 | 602
Total Pharmaceutical segment sales | International | Operating Segments | Remicade |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 135 | 214 | 459 | 651
Total Pharmaceutical segment sales | International | Operating Segments | Belsomra |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 43 | 30 | 115 | 78
Total Pharmaceutical segment sales | International | Operating Segments | Isentress/Isentress HD |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 151 | 167 | 477 | 474
Total Pharmaceutical segment sales | International | Operating Segments | Zepatier |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 86 | 241 | 339 | 680
Total Pharmaceutical segment sales | International | Operating Segments | Zetia |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 157 | 255 | 662 | 723
Total Pharmaceutical segment sales | International | Operating Segments | Vytorin |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 92 | 148 | 402 | 451
Total Pharmaceutical segment sales | International | Operating Segments | Atozet |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 84 | 59 | 258 | 171
Total Pharmaceutical segment sales | International | Operating Segments | Adempas |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 94 | 70 | 238 | 221
Total Pharmaceutical segment sales | International | Operating Segments | Januvia |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 429 | 414 | 1,291 | 1,153
Total Pharmaceutical segment sales | International | Operating Segments | Janumet |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 339 | 316 | 1,067 | 933
Total Pharmaceutical segment sales | International | Operating Segments | NuvaRing |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 41 | 54 | 135 | 148
Total Pharmaceutical segment sales | International | Operating Segments | Implanon/Nexplanon |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 53 | 45 | 160 | 137
Total Pharmaceutical segment sales | International | Operating Segments | Singulair |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 156 | 145 | 505 | 522
Total Pharmaceutical segment sales | International | Operating Segments | Cozaar/Hyzaar |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 99 | 119 | 330 | 345
Total Pharmaceutical segment sales | International | Operating Segments | Nasonex |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 64 | 65 | 266 | 250
Total Pharmaceutical segment sales | International | Operating Segments | Arcoxia |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 83 | 80 | 249 | 272
Total Pharmaceutical segment sales | International | Operating Segments | Follistim AQ |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 34 | 41 | 115 | 128
Total Pharmaceutical segment sales | International | Operating Segments | Fosamax |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 42 | 48 | 155 | 173
Total Pharmaceutical segment sales | International | Operating Segments | Dulera |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 6 | 7 | 21 | 19
Total Pharmaceutical segment sales | International | Operating Segments | Other Pharmaceutical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 666 | 688 | 2,150 | 2,140
Total Animal Health segment sales | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 1,021 | 1,000 | 3,176 | 2,894
Total Animal Health segment sales | Operating Segments | Livestock |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 660 | 655 | 1,946 | 1,816
Total Animal Health segment sales | Operating Segments | Companion Animals |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 361 | 345 | 1,230 | 1,078
Total Animal Health segment sales | United States | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 306 | 290 | 924 | 842
Total Animal Health segment sales | United States | Operating Segments | Livestock |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 153 | 137 | 383 | 359
Total Animal Health segment sales | United States | Operating Segments | Companion Animals |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 153 | 153 | 541 | 483
Total Animal Health segment sales | International | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 715 | 710 | 2,252 | 2,052
Total Animal Health segment sales | International | Operating Segments | Livestock |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 508 | 518 | 1,563 | 1,457
Total Animal Health segment sales | International | Operating Segments | Companion Animals |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 207 | 192 | 689 | 595
Other segment sales | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 55 | 100 | 195 | 294
Other segment sales | United States | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 55 | 100 | 194 | 294
Other segment sales | International | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | $ 0 | $ 0 | $ 1 | $ 0

X
- Definition The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585 + Details
Name: | us-gaap_ProceedsFromSaleOfIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=mrk_InternationalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_KeytrudaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_EmendMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_TemodarMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AlliancerevenueLynparzaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_LenvimaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_GardasilGardasil9Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ProQuadMMRIIVarivaxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_Pneumovax23Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_RotateqMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ZostavaxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_BridionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_NoxafilMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_InvanzMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_CubicinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_CancidasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_PrimaxinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_SimponiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_RemicadeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_BelsomraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_IsentressIsentressHDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ZepatierMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ZetiaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_VytorinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AtozetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AdempasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_JanuviaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_JanumetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_NuvaringMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ImplanonNexplanonMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_SingulairMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_CozaarHyzaarMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_NasonexMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ArcoxiaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_FollistimAqMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_FosamaxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_DuleraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_OtherPharmaceuticalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_LivestockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_CompanionAnimalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |